Subcutaneous Injection of Trastuzumab – Analysis of Administration Time and Injection Site Reactions

Pivot, X.; Semiglazov, V.; Chen, S.; Moodley, S.D.; Manihkas, A.; Coccia-Portugal, M.A.; Johnston, M.; van der Horst, T.; Bouhlel, A.; Jackisch, C.

doi:10.1016/s0923-7534(20)32834-9

Cited by 8Intramuscular injections and effectsHER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

The DOI matches its Crossref record.

Subcutaneous Injection of Trastuzumab – Analysis of Administration Time and Injection Site Reactions

Open access

Pivot, X., Semiglazov, V., Chen, S., Moodley, S.D., Manihkas, A., Coccia-Portugal, M.A., Johnston, M., van der Horst, T., Bouhlel, A., Jackisch, C.·2012·Annals of Oncology

DOI 10.1016/s0923-7534(20)32834-9

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/s0923-7534(20)32834-9

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

HannaH demonstrated that the duration of subcutaneous injections was generally between 1 and 5 min (average 3.3 min) compared with 30-90 min for intravenous administration.
“HannaH demonstrated that the duration of subcutaneous injections was generally between 1 and 5 min (average 3.3 min) compared with 30–90 min for intravenous administration [40].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [40]

Still being checked.

Sorted by citations

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Self-citation
A Multidisciplinary Perspective on the Subcutaneous Administration of Trastuzumab in HER2-Positive Breast Cancer
Dent, S. F., Ammendolea, C., Christofides, A., Edwards, S., Incekol, D., Pourmirza, B., Kfoury, S., & Poirier, B. (2019) · Current Oncology · doi:10.3747/co.26.4220 · Cited by 31
Patient Centricity Driving Formulation Innovation: Improvements in Patient Care Facilitated by Novel Therapeutics and Drug Delivery Technologies
Page, S., Khan, T. A., Kühl, P. G., Schwach, G., Storch, K., & Chokshi, H. P. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-093517 · Cited by 28
White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example
Jackisch, C., Manevy, F., Frank, S., Roberts, N., & Shafrin, J. T. (2022) · Advances in Therapy · doi:10.1007/s12325-021-01996-0 · Cited by 24
Self-citation
Evaluating nurse preferences for a novel on-body delivery system vs. manual syringes for large-volume subcutaneous drug administration: a survey study
Desai, M. G., Faiman, B. M., Gorski, L. A., Miles, A., Sterlin, V., & Curry, N. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2484278 · Cited by 12
Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients
Elsamany, S. A., Elsisi, G. H., Hassanin, F., & Jafal, M. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1860024 · Cited by 7
Current models, challenges and best practices for work conducted between European academic cooperative groups and industry
Stahel, R. A., Lacombe, D., Cardoso, F., Casali, P. G., Negrouk, A., Marais, R., Hiltbrunner, A., Vyas, M., Varoqueaux, N., Frohn, C., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000628 · Cited by 6

1946 A survey of the time and resource use of subcutaneous administration of trastuzumab compared to intravenous treatment in patients with breast cancer
Olofsson, S., Norrlid, H., Wilking, U., Karlsson, E., & Tennvall, G. R. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)30894-2
On the Horizon
Susman, E. (2015) · Oncology Times · doi:10.1097/01.cot.0000465752.51660.68
Abstract P3-12-04: Is 6 hour monitoring for administration related reactions after first administration of subcutaneous trastuzumab necessary? A single institution audit
Karmali, S., Hughes, N., Galiauskas, R., Cook, J., Murphy, K. D., Bird, B., & Murphy, C. (2017) · Cancer Research · doi:10.1158/1538-7445.sabcs16-p3-12-04 · Cited by 1
Abstract P4-16-08: A regional audit of 6-hour monitoring for administration related reactions during the first administration of subcutaneous trastuzumab
Karmali, S., Hughes, N., Kinneally, A., Kroes, J., Cook, J., Killian, M., Shafiq, T., O’Mahony, D., Bird, B., O’Connor, M., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-p4-16-08 · Cited by 1
Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast Cancer
Wynne, C., Harvey, V. J., Schwabe, C., Waaka, D., McIntyre, C., & Bittner, B. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012436560 · Cited by 127

Authors: Pivot, X., Semiglazov, V., Chen, S., Moodley, S. D., Manihkas, A., Coccia-Portugal, M. A., Johnston, M., van der Horst, T., Bouhlel, A., & Jackisch, C.
ORCID: Pivot, X.
Moodley, S.D.
Jackisch, C.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2012-09
Volume: 23
Pages: ix103
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1016/s0923-7534(20)32834-9
OpenAlex: W2998842913
Cited by: 8
References: 0
Citations by year: 2025: 1 · 2022: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2013: 1
FWCI: 0.36
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2688 d)
Locations: Annals of Oncology (publishedVersion)
Topics: Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords: trastuzumab, subcutaneous injection, administration time, injection site reactions, breast cancer, HER2-targeted therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Subcutaneous Injection of Trastuzumab – Analysis of Administration Time and Injection Site Reactions

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks